<scp>UGT1A1</scp>*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan
This retrospective, real-world analysis suggests potential clinical utility in UGT1A1 testing for patients receiving sacituzumab, but future trials are needed to confirm the association between genotypes and treatment outcomes.
Authors
- Daphne Stewart (ORCID: https://orcid.org/0000-0001-9845-8375)
- Joanne Mortimer (ORCID: https://orcid.org/0000-0002-2935-1934)
- James Waisman (ORCID: https://orcid.org/0000-0003-2896-4146)
- Veronica Jones (ORCID: https://orcid.org/0000-0003-2084-6815)
- Mina S. Sedrak (ORCID: https://orcid.org/0000-0002-8379-391X)
- Megan Wong (ORCID: https://orcid.org/0000-0003-3799-4400)
- Sayeh Lavasani
- Wai Yu
- Linda D. Bosserman (ORCID: https://orcid.org/0000-0003-3897-4276)
- Niki Patel
- Yuan Yuan (ORCID: https://orcid.org/0009-0002-9540-2100)
Institutions
- City of Hope (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/cam4.70096
- Citations
- 13
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- National Institutes of Health
- National Cancer Institute